{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-296205","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2021-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.427214+00:00","generated_at":"2026-06-28T21:30:03.073138+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Reneo Pharma appoints Ashley F. Hall as Chief Development Officer","bullets":["Hall previously CDO at Esperion; oversaw regulatory for NEXLETOL, NEXLIZET, and REPATHA.","Base salary $420,000, bonus up to 40%, housing reimbursement up to $5,000/month.","Relocation assistance of $150,000 if relocated within 18 months.","Equity inducement: option for 180,000 shares (4-yr vest) and RSU for 30,000 shares (vests on first NDA/MAA).","Severance: 9 months base/COBRA; on change in control 12 months plus full equity acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-296205","json":"https://secwatch.observer/filing/0001193125-21-296205.json","markdown":"https://secwatch.observer/filing/0001193125-21-296205.md","text":"https://secwatch.observer/filing/0001193125-21-296205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312521296205/0001193125-21-296205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312521296205/d239269d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T21:30:03.073138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bd09859dd","claim":"Ashley F. Hall was appointed as Chief Development Officer at OnKure Therapeutics, Inc..","evidence_excerpt":"On October 11, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) announced the appointment of Ashley F. Hall, J.D., as the Chief Development Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312521296205/0001193125-21-296205-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}